These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 25268476)

  • 1. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
    Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
    PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
    Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
    Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells.
    Hedlund M; Nagaeva O; Kargl D; Baranov V; Mincheva-Nilsson L
    PLoS One; 2011 Feb; 6(2):e16899. PubMed ID: 21364924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes and the MICA-NKG2D system in cancer.
    Clayton A; Tabi Z
    Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.
    Crane CA; Austgen K; Haberthur K; Hofmann C; Moyes KW; Avanesyan L; Fong L; Campbell MJ; Cooper S; Oakes SA; Parsa AT; Lanier LL
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12823-8. PubMed ID: 25136121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
    von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G
    Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
    Cerboni C; Ardolino M; Santoni A; Zingoni A
    Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
    Mincheva-Nilsson L; Baranov V
    Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X; Li CR; Yang J; Wang GB
    Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.